Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Nov;106(10):1229-37.
doi: 10.1172/JCI11066.

Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha

Affiliations

Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha

S Cenci et al. J Clin Invest. 2000 Nov.

Abstract

Estrogen deficiency induces bone loss by upregulating osteoclastogenesis by mechanisms not completely defined. We found that ovariectomy-enhanced T-cell production of TNF-alpha, which, acting through the TNF-alpha receptor p55, augments macrophage colony-stimulating factor-induced (M-CSF-induced) and RANKL-induced osteoclastogenesis. Ovariectomy failed to induce bone loss, stimulate bone resorption, or increase M-CSF- and RANKL-dependent osteoclastogenesis in T-cell deficient mice, establishing T cells as essential mediators of the bone-wasting effects of estrogen deficiency in vivo. These findings demonstrate that the ability of estrogen to target T cells, suppressing their production of TNF-alpha, is a key mechanism by which estrogen prevents osteoclastic bone resorption and bone loss.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ovariectomy fails to increase osteoclast formation in cultures of bone marrow cells from nude mice. Mean (± SEM) number of osteoclasts from three independent experiments (n = 6 wells per group). AP < 0.05 compared to estrogen replete mice. (a) Unfractionated bone marrow cells (106 cells/well) from OVX and estrogen-replete nude and euthymic mice were harvested 4 weeks after surgery and cultured for 7 days with 1,25(OH)2D3 (10–8M) to induce osteoclast formation. (b) Bone marrow cells were depleted of stromal cells by adherence for 12 hours. Nonadherent bone marrow cells (106 cells/well) were cultured for 7 days with optimal osteoclastogenic concentrations of M-CSF (25 ng/ml) and RANKL (100 ng/ml). OC, osteoclast.
Figure 2
Figure 2
T cells from OVX mice produce a soluble factor upregulating RANKL- and M-CSF–induced osteoclast formation, which is blocked by TNF-α neutralization. Mean (± SEM) of three independent experiments (n = 6 wells per group). AP < 0.05 compared with all other groups. (a) Cocultures of purified monocytes and purified T cells from OVX and estrogen-replete mice stimulated with optimal osteoclastogenic concentrations of M-CSF and RANKL. No osteoclast formation was observed in RANKL- and M-CSF–stimulated cultures of T cells in the absence of BMMs. Similarly, osteoclast differentiation of BMMs was not induced by stimulation with either RANKL or M-CSF alone, both in the presence or the absence of T cells (not shown). (b) Purified monocytes from intact mice stimulated with optimal osteoclastogenic concentrations of M-CSF and RANKL were cultured with either purified T cells from OVX and estrogen-replete mice or T cell–conditioned media (C.M.) from OVX and estrogen-replete mice. AP < 0.05 compared with all other groups.
Figure 3
Figure 3
T cells from OVX mice fail to increase RANKL- and M-CSF–induced osteoclast differentiation of monocytes lacking the p55 TNF-α receptor. Mean (± SEM) number of osteoclasts from three independent experiments (n = 6 wells per group). BMMs were purified from C57BL/6 mice lacking either TNF-α receptor 1 (p55–/–) or TNF-α receptor II (p75–/–) and WT controls of the same genetic background and cocultured with T cells derived from OVX or estrogen-replete WT mice in the presence of optimal concentrations of RANKL and M-CSF. AP < 0.05 compared with all groups.
Figure 4
Figure 4
Ovariectomy increases T-cell secretion of TNF-α. (a) TNF-α levels secreted by purified BMMs and T cells. Mean (± SEM) levels in culture supernatants from three independent experiments (n = 6 wells per group). P < 0.05 compared with all other groups. Culture media was collected after 3 days and TNF-α measured by ELISA as described (15). (b) TNF-α levels in cocultures of BMMs and T cells. Mean (± SEM) levels in culture supernatants from three independent experiments (n = 6 wells per group). P < 0.05 compared with all other groups. (c) TNF-α augments RANKL- and M-CSF–induced osteoclast formation in a dose-dependent manner. Mean (± SEM) number of osteoclasts from three independent experiments (n = 6 wells per dose). Purified monocytes from control mice were stimulated with M-CSF (25 ng/ml), RANKL (100 ng/ml), and TNF-α (0–10 ng/ml), and cultured for 7 days. AP < 0.05 compared with control.
Figure 5
Figure 5
Ovariectomy increases T-cell proliferation and bone marrow T-cell content. Mean (± SEM) of three independent experiments (n = 6 wells per group). AP < 0.05 compared with baseline. (a) Unstimulated T cells purified from OVX and estrogen-replete mice were cultured for 48 hours. At the end of the culture, T cells were counted. (b) Freshly isolated whole bone marrow was analyzed by FACS using anti-CD90 Ab. Total number of bone marrow cells was counted. Results are expressed as number of T cells per femur.
Figure 6
Figure 6
Ovariectomy fails to induce bone loss and upregulate bone turnover in nude mice (n = 6 per group). AP < 0.05 compared with all other groups. BP < 0.05 compared with sham nu/nu. (a) Trabecular BMD (mean ± SEM) of the tibia was measured 4 weeks after surgery in excised tibiae using pQCT. (b) DPD excretion (mean ± SEM) at 4 weeks after surgery. (c) Serum osteocalcin levels (mean ± SEM) at 4 weeks after surgery.
Figure 7
Figure 7
Histology of nude mice femur. Note that sham (top panel), OVX (middle panel), and estrogen-treated OVX (bottom panel) had similar cortical thickness and lack of trabecular bone resorption below the growth plates. The three groups had similar number of TRAP-positive osteoclasts (stained in red).

Comment in

References

    1. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176. - PubMed
    1. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315–323. - PubMed
    1. Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597–3602. - PMC - PubMed
    1. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Engl J Med. 1995;332:305–311. - PubMed
    1. Pacifici R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 1996;11:1043–1051. - PubMed

Publication types

MeSH terms

Substances